COMPUMEDICS LIMITED — Capital/Financing Update 2014

Jun 4, 2014

==> picture [74 x 64] intentionally omitted <==

ASX Announcement 5 June 2014

**SECOND

MAJOR US CONTRACT WIN GIVES COMPUMEDICS ACCESS TO 2,800 ADDITIONAL HOSPITALS**

Highlights:

• Compumedics signs 3-­‐year agreement with MedAssets Purchasing Group as a preferred vendor for the purchase of sleep diagnostic and neuro-­‐monitoring systems to their member group

• MedAssets membership comprises nearly 2,800 hospitals and 90,000 acute healthcare facilities across the US

Compumedics Limited (ASX: CMP) is pleased to announce that its wholly owned subsidiary,Compumedics USA, Inc. has won a 3-­‐year agreement with MedAssets Purchasing Group (“MedAssets”) for the purchase of Compumedics sleep diagnostic and neuro-­‐monitoring systems. Under this agreement MedAssets will provide its members with access to purchase Compumedics’ range of sleep diagnostic and neuro-­‐monitoring systems.

The MedAssets member network consists of 2,800 hospitals and 90,000 acute healthcare facilities across the US. . Compumedics is one of only two vendors that have been given preferred vendor status for sleep diagnostic and neuro-­‐monitoring systems to the MedAssets Purchasing Group.

This announcement follows Compumedics’ recent purchasing contract deal with The HealthTrust member network announced to the ASX on 9th April 2014, which consists of 1,400 hospitals and 10,600 non-­‐acute healthcare facilities across America. With HealthTrust Purchasing Group, Compumedics was also one of only two vendors that have been given preferred vendor status for sleep diagnostic and neuro-­‐monitoring systems.

For more than 25 years, healthcare providers worldwide have chosen Compumedics’ comprehensive and innovative line of sleep diagnostic and neuro–monitoring systems to aid in the diagnosis, information and treatment of their patients. This new MedAssets contract confirms the enduring nature of Compumedics’ proposition to deliver innovative solutions to market.

Compumedics remains highly focused on growing the Group’s earnings and sustainable profitability through:

• Expansion of the Company’s existing products to all key global markets;

• Expansion of sales of the Company’s existing products into emerging markets, particularly China; and

• Continuing the initial penetration of the neuro-­‐diagnostic market, particularly the US, with Compumedics’range of neuro-­‐diagnostic products, including the Neuvo ® LTEM (long-­‐term EEG-­‐ monitoring) system

**In

commenting on this new deal for the Company, Executive Chairman & CEO, Dr David Burton said:**

“We are delighted to announce another substantial contract win for Compumedics. MedAssets Purchasing Group is one of the major member networks for hospitals in the US market and to sign a 3-­‐year agreement with them, giving access to 2,800 hospitals is a significant milestone achievement for our Company. Together with the recent announcement of a similar contract win with the HealthTrust Purchasing Group it provides a solid basis for the US business to grow and prosper through FY2015 and beyond.”

==> picture [74 x 64] intentionally omitted <==

**About

Compumedics Limited**

Compumedics Limited (ASX: CMP) is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-­‐flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including Americas; Australia and Asia Pacific; and Europe and the Middle East.

Compumedics was founded in 1987 by Executive Chairman, Dr David Burton. In the same year the Company successfully designed and installed the first Australian, fully computerised Sleep Clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets. Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards and accolades and has been recognised by the Australian Innovation Government and Industry Body as one of Australia's Top 100 Health Innovators through its world leading devices for sleep diagnostics.

**About

MedAssets**

MedAssets is at the center of improving the quality and effectiveness of the healthcare industry. From establishing best practice value for clinical and labor resources to supply pricing and procurement processes to reimbursement accuracy to payor contract management and modelling—our solutions, industry experts and data-­‐driven methodologies are helping healthcare enterprises make informed changes to drive total cost reduction, financial optimization, clinical delivery alignment and efficiency.

For further information please contact:

Dr David Burton , Executive Chairman, CEO Compumedics Limited T: + 61 3 8420 7300, F: +61 3 8420 7399

Mr David Lawson , Executive Director, CFO Compumedics Limited T: + 61 3 8420 7300, F: +61 3 8420 7399

For investor relations and media enquiries please contact:

Rod North , Managing Director, Bourse Communications Pty Ltd T: (03) 9510 8309, M: 0408 670 706 E: rod@boursecommunications.com.au